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Two tetrahydocarbazolone derivatives were found to show 
multiple unsolvated crystal forms. A persistent dimer motif 
was detected in solution by FTIR spectroscopy that is 
maintained in the kinetic crystal forms. Rationally 
introduced steric bulk induces the formation of a more 
stable catemeric form. 
Different crystal forms (polymorphs) may vary substantially in their 
physico-chemical characteristics, including melting point, chemical 
and physical stability, solubility and dissolution rate, the latter of 
which represents both a challenge and an opportunity for the 
pharmaceutical industry.1 Thus, polymorphism studies are an 
ongoing focus during the development of new drug compounds, and 
studies of the solute-solute and solute-solvent interactions prior to 
crystallisation,2 as well as those during the nucleation process itself 
have become highly topical.3 Bioactive molecules and 
pharmaceuticals typically have multiple functional groups, enabling 
them to interact with receptors and thus show pharmacological 
action. Furthermore, as drug molecules become ever larger, they 
tend to show increased flexibility. These two factors make 
investigations and predictions of the crystallisation behaviour of 
most drug molecules inherently difficult.4 Therefore, to understand 
the factors leading to polymorphism, model compounds with 
reduced complexity have to be investigated, which allow the 
influence of, e.g., individual functional groups to be deconvoluted.5 
In this study, we chose to investigate tetrahydrocarbazolone 
derivatives (Scheme 1), as they represent core fragments of many 
antibacterial and antiviral drugs and prodrugs,6 whilst having a rigid 
core with only one hydrogen-bond (HB) donor and one HB acceptor 
functionality. We were particularly interested in understanding 
whether these compounds show predictable supramolecular 
synthons7 that are robust enough to persist from a self-assembled 
pre-aggregated structure in solution to the solid state,8 and therefore 
influence the observed polymorphism, and whether it is possible to 
perturb these synthons by manipulation of the steric bulk of the 
molecule in order to affect the crystallisation outcome.  
A search for known crystal structures of the 
tetrahydrocarbazolone fragment in the Cambridge Structural  
 
Scheme 1 Molecular structure of the tetrahydrocarbazolone 
derivatives investigated in this study. 
 
Database9 returned a total of 22 crystal structures (search inputs are 
shown in the ESI). A total of 19 of these exhibit hydrogen-bonded 
centrosymmetric dimer formation through two complementary HBs 
between the N–H and C=O groups. In each case the interaction 
between donor and acceptor is not completely linear but exhibits a 
lateral offset of the acceptor in the direction of the aromatic ring (Fig 
S1). A search for the cyclopentenone analogue found seven 
structures, all of which contain the dimer motif; however, no hits 
were found for the cycloheptenone analogue. Simplifying the search 
to partially saturated indol-7-one derivatives found an additional 15 
structures, with only four structures showing dimer formation, whilst 
a search for partially saturated quinolin-8-one derivatives gave eight 
structures, of which two contain the dimer synthon. However, the 
structures in the latter datasets have a high number of HB donor and 
acceptor groups, which make the realisation of other, competing 
synthons possible. Several hydrates were also retrieved that do not 
form the dimer motif, as a result of interactions with the water 
molecules. Overall, the high prevalence of the dimer motif for this 
group of related compounds indicates that this synthon is quite 
robust. 
With this in mind, we initially chose a tetrahydrocarbazolone 
derivative with a methyl group in the 7-position of the indole ring 
(‘ortho-methyl carbazolone’, OCB), i.e. in the direct vicinity of the 
HB-donating N-H group. This substitution pattern was anticipated to 
weaken the hydrogen-bonded dimers due to steric hindrance and 
reduce the possibility of realising the seemingly stabilising offset of 
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the molecules against one another. We note that steric destabilisation 
of otherwise robust supramolecular synthons has been implicated 
previously in the formation of unusual helical structures of both 
carboxylic acids10 and benzyl alcohols11 and more generally in 
determining the structures of bulky monoalcohols.12 
A polymorphism screen of OCB was carried out using slow and 
fast cooling experiments. For both experiment types, a saturated 
solution at boiling point was prepared in a total of 20 solvents of 
differing polarity and HB-accepting and -donating strengths. In 
addition, crystallisation from the melt and by sublimation using hot-
stage microscopy was performed. Four different unsolvated crystal 
forms were identified and characterised by FTIR spectroscopy and 
powder X-ray diffraction (see ESI Figures S2 and S3). All forms 
could be crystallised from solution, as well as from the melt. The 
different modifications can be differentiated by FTIR spectroscopy, 
even though the overall changes are small. The most pronounced 
difference is between the N-H vibrations of form I and the group of 
forms II, III and IV in the region 3350-3150 cm-1. Forms II, III and 
IV show peaks at 3286, 3291 and 3288 cm-1, respectively, while the 
peak of form I is shifted to considerably lower energy at 3227 cm-1. 
Thus, it was concluded that the HB-donor interactions of form I have 
to be significantly different from those of forms II, III and IV, which 
themselves should be closely related to one another. 
The crystallisation experiments yielded crystals of sufficient size 
and quality to obtain X-ray single-crystal structures. All four crystal 
forms are presented in Figure 1, of which form III has been 
described previously by Archana et al. (CSD ref. SUZGIE).13 
 
 
Figure 1 Crystal packing of the four polymorphs of OCB as 
determined by single-crystal X-ray diffraction. 
 
OCB crystal forms II, III and IV (Fig. 1) consist of the expected 
dimers generated by crystallographic inversion centres. The planes 
of the two molecules in all dimers are parallel, but show different 
plane-to-plane offsets. Due to staggering, the HB angle (D···A) 
changes from 156° in form II to 165° in forms III and IV. The N···O 
distance is consistently 2.84–2.86 Å. As a secondary motif, the 
dimers stack into a herringbone pattern generated by glide planes; 
however, the angles between the stacks vary widely. Form II shows 
the shallowest angle of 89.3° between neighbouring stacks; the 
stacks in form IV are oriented at 67.4°, while form III has the 
steepest packing with an angle of 46.5° (Fig 1). The only short 
contacts between sets of dimers are weaker C-H···π interactions. 
Form I, however, shows catemer formation, i.e. infinite chains of 
hydrogen-bonded molecules that are generated by a 21 screw 
operation along the crystallographic a-axis with an angle between 
the molecular planes of 88.4°. The hydrogen bonds are nearly linear 
on the donating side (N-H···O angle of 166°) but rather angled on 
the accepting side (C=O···N angle of 113°), with a distance of 
2.871(3) Å. The chains are packed in alternating stacks, which are 
related by a 21 screw operation along the crystallographic c-axis. 
This behaviour of OCB mirrors that of carbamazepine, an anti-
convulsant and mood-stabilising drug, for which stable dimer and 
catemer crystal forms were predicted in silico.14 However, the 
catemer form proved to be elusive for a long time and was only 
obtained recently by seeding the vapour phase with a catemer-
forming structural analogue.15 While the catemer of OCB 
crystallised without cross-seeding, it requires considerable time to 
nucleate – up to several weeks in some solvents. It was also 
observed that samples of forms III and IV transformed into form I 
over time when stored as a suspension at room conditions (Table 
S1). Form II and IV were additionally found to transform into form 
III under the same conditions. Thus, despite evident kinetic 
inhibition, it is concluded that form I is the thermodynamically 
stable polymorph at room temperature, followed by form III as the 
most stable dimer crystal form in this system. This fact highlights 
the importance of a thorough polymorphism screening, because the 
occurrence of a stable polymorph after a long nucleation time could 
easily be missed and could lead to incidents such as that of 
ritonavir.16 
Non-empirical lattice energy calculations using the Partial Charges 
and Chemical Hardness Algorithm PACHA17 give insight into the 
relative strengths of the HBs in the crystal forms. Surprisingly, the 
stabilising energies of the dimers and the catemer vary only within 
the range 19.9–23.8 kJ mol-1, with the thermodynamically stable 
form I not having the strongest interactions. However, the ranking of 
the calculated densities of the crystal structures obeys the density 
rule of Burger and Ramberger,18 i.e., the most stable form is the 
densest, and thermomicroscopic investigations confirmed that form I 
which melts at 174 °C has the highest melting point of all OCB 
crystal forms (form II: 168 °C, form III: 169-170 °C, form IV: 172 
°C), thus suggesting monotropic relationship of all crystal forms 
with form I, with the latter being the most stable over the whole 
temperature range. 
Having determined that form I has a longer induction time than the 
other forms, the hypothesis was postulated that OCB exists as dimers 
in solution, the melt and the vapour phase, which crystallise into the 
crystal forms II, III and IV upon rapid nucleation. If the 
crystallisation experiment is performed slowly however, so that the 
solution can age, the dimers convert into catemers, and subsequently 
the most stable polymorph, form I, crystallises. To prove initial 
solution dimerisation, an FTIR titration was performed by starting 
with a 0.542 M solution of OCB in chloroform (close to saturation) 
and conducting a serial dilution. At the highest concentration, two 
different N-H vibrations can clearly be observed, namely a sharp 
feature at 3460 cm-1 and a broader peak around 3300 cm-1 (Fig. 2). 
According to quantum calculations (vide infra), the higher energy 
peak corresponds to the OCB monomer, while the lower energy 
feature originates from the dimer. This assignment is corroborated 
by the titration: with decreasing concentration, the lower energy 
peak vanishes to the point that at a concentration of 0.018 M it is not 
detectable above the background. The monomer N-H vibration, 
however, is still observable at this low concentration (Figure S4).  
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Figure 2 N-H region of the normalised transmission FTIR spectra of 
a 0.542 M solution of OCB in chloroform and the four crystal forms. 
Vertical lines depict the DFT-calculated N-H vibrations of the 
monomer and dimer. 
 
When the solution IR spectra are compared with the solid-state 
spectra of forms I-IV, it can be seen that the species formed in 
solution is indeed the dimer, as the N-H vibration is very similar in 
energy to that of the three dimer crystal forms, forms II, III, and IV. 
The N-H vibration of form I is shifted to significantly lower energy, 
and is clearly distinct from that observed in solution, excluding the 
possibility of catemer-like chains in chloroform solution. 
A similar preliminary dimer formation is anticipated in the gas 
phase, as crystals formed by sublimation are form III, i.e. the most 
stable modification showing the dimer motif. This crystallisation 
method is the only one that did not result in the formation of form I 
under any conditions. Crystallisation from the melt typically resulted 
in one of the dimer polymorphs, but form I could be grown by 
annealing the melt at temperatures above the melting points of the 
dimer modifications (>170 °C). The overall crystallisation behaviour 
therefore supports the hypothesis that, before crystallisation occurs, 
the amorphous phase consists of OCB dimers, be it in solution, the 
vapour phase or the melt. 
In order to investigate the influence of the methyl group in the 
vicinity of the HB donor on the resultant crystallisation behaviour, 
another tetrahydrocarbazolone molecule was investigated, in which 
the methyl group was changed from the 7- to the 5-position of the 
indole ring (‘para-methyl carbazolone’, PCB, Scheme 1). A 
crystallisation screen was carried out in a similar way to OCB (Table 
S3) and the resulting crystal forms were characterised by FTIR 
spectroscopy and powder X-ray diffraction (Figures S5 and S6). At 
least five different polymorphs could be identified, with some of 
them occurring concomitantly and some indication of additional 
modifications that could not be obtained as pure phases. The crystal 
forms were named forms I to V according to their order of 
appearance in time. Forms I, IV and V could only be crystallised 
from solution, while forms II and III were only obtained from the 
melt. FTIR spectroscopic investigations indicated that all forms 
exhibit the dimer motif, as all N-H vibrations coincide within the 
narrow range of 3369 to 3366 cm-1, comparable to the dimer forms 
of OCB. Even though the existence of a catemer form cannot be 
completely excluded, we can be sure that it is not accessible in a 
reasonable experimental space. In addition, cross-seeding 
experiments of PCB melt or solutions with the catemer form of 
OCB, form I, resulted in the crystallisation of a random but pure 
dimer modification of PCB, and thus, unlike the analogous case of 
carbamazepine, a catemer form cannot be easily produced by this 
method. 
Powder X-ray diffractograms showed that samples crystallised 
from solution and identified as form I are generally a mixture of 
several forms including predominantly form I as well as form V and 
additional phases, indicating that the energetic differences between 
the PCB polymorphs are small and that more modifications are 
likely to exist. Further investigations into this behaviour are 
underway. 
Three modifications could be crystallised in sufficient quality to 
determine their X-ray crystal structures, namely form I, form IV and 
form V (Fig. 3 and Table S4). These crystal structures are very 
closely related and show almost identical packing, corroborating the 
possibility that more energetically closely related crystal forms exist. 
In particular, forms I and V, which crystallise concomitantly, reveal 
the same geometry of the dimers and have the same packing with the 
only subtle difference being that both forms crystallise in layers, 
which in form I are oriented so that the methyl group of adjacent 
dimers are on opposite sides, while in form V these are on the same 
side. This results in different space groups for the two structures 
(form I in P21/n, form V in Pbca). Even though the chemical 
structures of OCB and PCB are similar, the packing schemes in the 
respective crystal structures are very different, and no pair of them is 
isostructural. 
The structures of OCB, PCB and their respective 𝑹𝟐
𝟐(𝟏𝟎) 
hydrogen-bonded homodimers were optimised in the gas phase 
using DFT calculations (B3LYP/6-311+G(d), GD3BJ dispersion 
correction). The dimerisation energies in the gas phase are calculated 
to be –70.2 and –74.4 kJ mol-1 for OCB and PCB, respectively. The 
slightly less exothermic dimerisation energy of OCB is presumably 
due to the destabilising steric interaction of the ortho-methyl group. 
This introduces a lateral displacement of the dimer within the near 
coplanar structure of ca. 0.45 Å, due to a close contact between the 
carbonyl and methyl groups of the two monomers (Figure S7). The  
 
Figure 3 Crystal packing of the three polymorphs of PCB as 
determined by single-crystal X-ray diffraction. 
 
calculated hydrogen-bonding distances are respectively 1.859 (O–H) 
/ 2.871 (N–O) and 1.847 (O–H) / 2.826 (N–O) Å for OCB and PCB, 
in good agreement with the experimental X-ray structures. 
Frequency calculations on the optimised monomer and dimer 
structures gave insight into our FTIR spectroscopic studies of OCB, 
namely that the N-H stretch of the monomer is higher in energy 
(3530 cm-1) than that of the hydrogen-bonded dimer (3349 cm-1). 
We believe that the destabilising steric interaction present in the 
dimeric structure of OCB that is absent in PCB is the driving force 
towards the formation of the catemeric structure, i.e. due to a 
weakening of the hydrogen bonding in the dimer, the catemer 
modification of OCB, in which this steric interaction is less 
pronounced, becomes lower in energy relative to the dimer structures 
and, thus, experimentally accessible. Kinetically, however, it is slow 
to form due to the entropic cost of forming chains. Furthermore, it 
can be presumed that to form a catemer chain would first require the 
breaking of hydrogen bonds in the initially formed dimers that will 
have a large activation energy due to the generation of unsaturated or 
weakly solvated hydrogen bond acceptors and donors. 
In addition, the dimer structure of FOCB, i.e. where the CH3 
of OCB is replaced with the larger CF3 group, was optimised in 
the gas phase at the same level of theory. The binding in the 
dimer (–55.7 kJ mol-1) is weaker than that of the OCB dimer, 
from which we might predict that this compound would be 
expected to form a catemeric structure; this hypothesis will be 
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tested in future work. The replacement of a methyl group with 
its bio-isostere CF3 is commonly performed in the development 
of pharmaceuticals, due to the greater metabolic stability of the 
latter; thus, while such a replacement may be desirable from a 
pharmokinetic view point, its influence on solid-state 
behaviour, and, subsequently, on the formulation of the drug 
into a dosage form, is less often considered. 
In conclusion, this study presents the polymorphism of two 
methyl-tetrahydrocarbazolone derivatives, and the influence of 
the position of methylation on the existence of supramolecular 
synthons. Ortho-methylated tetrahydrocarbazolone (OCB) can 
exist in four different crystal structures, three of which show 
the anticipated dimer formation. The thermodynamically stable 
polymorph, however, crystallises in a catemer motif but has a 
considerably longer nucleation time. This behaviour is 
reminiscent of carbamazepine, which was predicted to form a 
stable catemeric modification, but could only be crystallised as 
such by seeding with a structural analogue. The existence of a 
more stable polymorph with slower crystallisation kinetics can 
cause severe manufacturing problems in the pharmaceutical 
industry, as was the case with ritonavir. When moving the 
methyl group from the ortho- to the para-position (PCB), only 
dimer formation was observed, while the different polymorphs 
become very close in energy and concomitant crystallisation 
occurred. Thus, subtle changes in molecular structure can have 
profound influences on crystallisation behaviour. It is also 
predicted that a bio-isosteric replacement of the CH3 group of 
OCB with CF3 will further stabilise the catemer, highlighting a 
potential problem for the design of new drugs and their 
subsequent formulation into a dosage form. 
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